Based on apparent higher recanalization rates of the infarct-related artery, preferential use
of thrombolytic agents with high clot specificity has been proposed for treating patients with …

Numerous controlled clinical trials have documented the efficacy of thrombolytic agents in
reducing the risk of mortality after myocardial infarction (MI). As a result, it is no longer ethical …

Thrombotic complications of cardiovascular disease are a main cause of death and disability
and, consequently, thrombolysis could favorably influence the outcome of such life …

The results of an overview of early (90–240 min) and late (24 hours or more) patency and of
stroke rates for each of the three commercially available thrombolytic agents, streptokinase …

Coronary thrombolysis revolutionized the treatment of acute myocardial infarction. Most of
the experience was obtained with intravenous use of streptokinase and tissue‐type …

Plasminogen activators of distinct structure and biochemical action seem to be more
equivalent than unique regarding induced blood changes and clinical complications. All of …

Background—Early reinfarction after thrombolytic therapy is associated with adverse
outcomes and increased mortality. Among patients with reinfarction in the 1992 Global …

The" Thrombolysis in Myocardial Infarction"(TIMI) Trial, sponsored by the National Heart,
Lung and Blood Institute, has evaluated the efficacy of coronary recanalization in acute …

All thrombolytic agents convert plasminogen to plasmin, either directly, as in the case of
urokinase, saruplase, and alteplase, or indirectly, as in the case of streptokinase. In the …

Patients from 4 German multicenter studies on thrombolysis in acute myocardial infarction
(AMI) were retrospectively evaluated to assess the incidence of optimal reperfusion, defined …